Skip to main content
SpringerLink
Log in

Therapeutic approaches to metastasis confined to the liver

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Liver metastases nearly always represent disseminated cancer, and systemic therapies are usually indicated. However, in a minority of patients—some with colorectal cancer, others with selected tumors—management of the hepatic disease may be clinically important and even curative. This review identifies unique patient subgroups and novel treatment approaches that may be indicated in patients with liver metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039–2048. This study is significant for the apparent benefit of regional HIA therapy following liver metastasis resection in colorectal cancer. It is also important to note the excellent curative rate even for patients in the non-HIA chemotherapy arm.

    Article  PubMed  CAS  Google Scholar 

  2. Schneebaum S, Walker MJ, Young D, et al.: The regional treatment of liver metastases from breast cancer. J Surg Oncol 1994, 55:26–32.

    Article  PubMed  CAS  Google Scholar 

  3. Rivera E, Fraschini G, Esparza-Guerra L, et al.: Frontline arterial infusion chemotherapy for hepatic metastases in breast cancer patients. Cancer Ther 1999, 2:44–49.

    Google Scholar 

  4. Drougas JG, Anthony LB, Blair TK, et al.: Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumor. Am J Surg 1998, 175:408–412.

    Article  PubMed  CAS  Google Scholar 

  5. Ajani JA, Carrasco H, Charnsangavej C, et al.: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988, 108:340–344.

    PubMed  CAS  Google Scholar 

  6. Mavligit GM, Zukiwski AA, Salem PA, et al.: Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991, 68:321–323.

    Article  PubMed  CAS  Google Scholar 

  7. Venook AP, Eaton V, Chang J, et al.: Chemoembolization for liver metastases from uveal melanoma. GI Cancer 1996, 1:269–273.

    Google Scholar 

  8. Clarke MP, Kane RA, Steele G, et al.: Prospective comparison of preoperative imaging and intraoperative ultrasonagraphy in the detection of liver tumors. Surgery 1989, 106:849–855.

    PubMed  CAS  Google Scholar 

  9. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938–946.

    PubMed  CAS  Google Scholar 

  10. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995, 19:59–71.

    Article  PubMed  CAS  Google Scholar 

  11. Glasgow RE, Showstack JA, Katz PP, et al.: The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Arch Surg 1999, 134:30–35. This study provides evidence that patients with complicated cancer problems have better outcomes when managed in centers with extensive experience in the procedures being studied.

    Article  PubMed  CAS  Google Scholar 

  12. Begg CB, Cramer LD, Hoskins WJ, Brennan MF: Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998, 280:1747–1751.

    Article  PubMed  CAS  Google Scholar 

  13. Luna-Perez P, Rodrigues-Corio DF, Arroyo B, Gonzalez-Macouzet J: The natural history of liver metastases from colorectal cancer. Arch Med Res 1998, 29:319–324.

    PubMed  CAS  Google Scholar 

  14. Jarnagin WR, Fong Y, Ky A, et al.: Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 1999, 188:33–42. An important study to aid in the preoperative decision of the likelihood of a patient having resectable hepatic metastases.

    Article  PubMed  CAS  Google Scholar 

  15. Cady B, Jenkins RL, Steele GD, et al.: Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998, 227:566–571.

    Article  PubMed  CAS  Google Scholar 

  16. Elias D, Cavalcanti A, Sabourin J-C, et al.: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998, 69:88–93.

    Article  PubMed  CAS  Google Scholar 

  17. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 1999, 230:309–321.

    Article  PubMed  CAS  Google Scholar 

  18. Adam R, Bismuth H, Castaing D, et al.: Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997, 225:51–62.

    Article  PubMed  CAS  Google Scholar 

  19. Ravikumar T, Steele G: Hepatic cryosurgery. Surg Clin N Am 1989, 69:433–440.

    PubMed  CAS  Google Scholar 

  20. Onik G, Kane R, Steele G, et al.: Monitoring hepatic cryosurgery with sonography. AJR Am J Roentgenol 1986, 147:665–669.

    PubMed  CAS  Google Scholar 

  21. Curley SA, Izzo F, Delrio P, et al.: Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg 1999, 230:1–8. A realistic report on the potential role of RFA.

    Article  PubMed  CAS  Google Scholar 

  22. Jiao LR, Hansen PD, Havlik R, et al.: Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 1999, 177:303–306.

    Article  PubMed  CAS  Google Scholar 

  23. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969–985.

    PubMed  CAS  Google Scholar 

  24. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984, 2:498–504.

    PubMed  CAS  Google Scholar 

  25. Kemeny N, Daly J, Reichman B, et al.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987, 107:459–465.

    PubMed  CAS  Google Scholar 

  26. Hohn DC, Stagg RJ, Friedman MA, et al.: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern Oncology Group Trial. J Clin Oncol 1989, 7:1646–1654.

    PubMed  CAS  Google Scholar 

  27. Chang AE, Schneider PD, Sugarbaker PH, et al.: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685–693.

    Article  PubMed  CAS  Google Scholar 

  28. Martin JK, Jr., O’Connell MJ, Wieand HS, et al.: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990, 125:1022–1027.

    PubMed  Google Scholar 

  29. Rougier P, Laplanche AS, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112–1118.

    PubMed  CAS  Google Scholar 

  30. Allen-Mersh TG, Earlam S, Fordy C, et al.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  31. Allen-Mersh TG, Earlam S, Fordy C, Abrams K: Continuous hepatic artery floxuridine (FUDR) infusion prolongs overall and normal-quality survival in colorectal liver metastasis (CLM) patients [abstract]. Proc ASCO 1994, 13:202.

    Google Scholar 

  32. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88:252–258.

    Article  Google Scholar 

  33. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer 1996, 78:1639–1645.

    Article  PubMed  CAS  Google Scholar 

  34. Muller H-H: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243–254.

    PubMed  Google Scholar 

  35. Stagg RJ, Venook AP, Chase JL, et al.: Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991, 83:423–428.

    Article  PubMed  CAS  Google Scholar 

  36. Kemeny N, Seiter K, Niedzwiecki D, et al.: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic cancer. Cancer 1992, 69:327–334.

    Article  PubMed  CAS  Google Scholar 

  37. Kemeny N, Seiter K, Conti JA, et al.: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. Cancer 1994, 73:1134–1142.

    Article  PubMed  CAS  Google Scholar 

  38. Kemeny N, Conti JA, Cohen A, et al.: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994, 12:288–2295.

    Google Scholar 

  39. Venook AP: Update on hepatic intra-arterial chemotherapy. Oncology 1997, 11:947–957.

    PubMed  CAS  Google Scholar 

  40. Belluco C, Guillem JG, Kemeny N, et al.: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996, 14:2696–2701.

    PubMed  CAS  Google Scholar 

  41. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413–1418.

    Article  PubMed  CAS  Google Scholar 

  42. Rothenberg ML, Eckardt JR, Kuhn JG, et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14:1128–1135.

    PubMed  CAS  Google Scholar 

  43. Kemeny N, Cohen A, Seiter K, et al.: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993, 11:330–335.

    PubMed  CAS  Google Scholar 

  44. Levi FA, Zidani R, Vannetzel J-M, et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86:1608–1617.

    Article  PubMed  CAS  Google Scholar 

  45. Kemeny MM, Adak S, Lipsitz S, et al.: Results of the Intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases [abstract]. Proc ASCO 1999, 18:264a.

    Google Scholar 

  46. Lorenz M, Muller H-H, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998, 228:756–762.

    Article  PubMed  CAS  Google Scholar 

  47. Ron IG, Kemeny NE, Tong B, et al.: Phase I/II study of escalating doses of systemic irinotecan (CPT-11) with hepatic arterial infusion of floxuridine (FUDR) and dexamethasone (D), with or without cryosurgery for patients with unresectable hepatic metastases from colorectal cancer [abstract]. Proc ASCO 1999, 18:236a.

    Google Scholar 

  48. Stagg RJ, Venook AP, Chase JL, et al.: Chemoembolization of primary and metastatic liver tumors. Reg Cancer Treat 1992, 2:53–57.

    Google Scholar 

  49. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994, 12:1323–1334.

    PubMed  CAS  Google Scholar 

  50. Mavligit GM, Zukwiski AA, Ellis LM, et al.: Gastrointestinal leiomyosarcoma metastatic to the liver. Cancer 1995, 75:2083–2088.

    Article  PubMed  CAS  Google Scholar 

  51. Alexander HR, Bartlett DL, Libutti SK, et al.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998, 16:1479–1489.

    PubMed  CAS  Google Scholar 

  52. Anderson SC, Johnson DE, Harris MP, et al.: p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998, 4:1649–1659.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Francisco School of Medicine, University of California, Box 0324, 94143-0324, San Francisco, CA, USA

    Alan P. Venook MD & Robert S. Warren MD

Authors
  1. Alan P. Venook MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Warren MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Venook, A.P., Warren, R.S. Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 3, 109–115 (2001). https://doi.org/10.1007/s11912-001-0009-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0009-4

Keywords

Search

Navigation